Gene amplification as means for determining therapeutic strategies in human cancers1

Clinical Chemistry and Laboratory Medicine

Volumn 38, Issue 9, 2000, Pages 837-839

  Tsongalis, G J ^a   Cartun, R W ^a   Ricci A , Jr ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Breast cancer; Oncogene; Pharmacogenomics

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GENE PRODUCT; METHOTREXATE; PACLITAXEL; PROTEIN; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; LYMPH NODE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GENETIC DISEASES, INBORN; GENETIC MARKERS; GENOMICS; HUMANS; PHARMACOGENETICS; PROTEOME; RECEPTOR, ERBB-2;

EID: 0033760609     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Approach to small round cell tumors of childhood
2. Molecular pathology of human neuroblastoma
3. The biology of breast cancer
4. C-erbB-2 amplification in mammary carcinoma
5. Clinical significance of Her-2/neu oncogene amplification in primary breast cancer
6. The type 1 growth factor receptors in human breast cancer
7. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
8. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
9. Phase II study of weekly intravenous recombinant humanized anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
10. Phase II study of receptor enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory treatment
11. Clinical laboratory evaluation of erbB-2 oncogene amplification in primary human breast cancer
12. Evaluation of p185(HER2) overexpression in human breast cancer using molecular and immunohistochemical methods
13. ErbB-2 and response to doxorubicin in patients with axillary lymph node positive hormone receptor negative breast cancer
14. C-erbB-2 expression and response to adjuvant therapy in women with node positive early breast cancer